Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Income from Continuing Operations (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Income from Continuing Operations for 16 consecutive years, with 37419000.0 as the latest value for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 59.94% year-over-year to 37419000.0; the TTM value through Dec 2025 reached 122932000.0, down 25.52%, while the annual FY2025 figure was 122932000.0, 25.52% down from the prior year.
  • Income from Continuing Operations hit 37419000.0 in Q4 2025 for Sangamo Therapeutics, down from 34930000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 21133000.0 in Q1 2023 and bottomed at 114506000.0 in Q2 2023.
  • Average Income from Continuing Operations over 5 years is 42465400.0, with a median of 43596000.0 recorded in 2022.
  • Year-over-year, Income from Continuing Operations crashed 3063.26% in 2021 and then surged 148.01% in 2023.
  • Sangamo Therapeutics' Income from Continuing Operations stood at 37469000.0 in 2021, then crashed by 38.71% to 51973000.0 in 2022, then dropped by 16.01% to 60295000.0 in 2023, then skyrocketed by 61.2% to 23396000.0 in 2024, then plummeted by 59.94% to 37419000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 37419000.0, 34930000.0, and 19986000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.